Human Cells' 'Viral Alarm Switch' Uncovered by CSIR-CCMB Scientists
Scientists at CSIR-CCMB Hyderabad identify DZIP3 protein as a viral alarm switch, paving the way for new broad-spectrum antiviral therapies.
In a groundbreaking leap for immunology, scientists at the CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB) in Hyderabad have uncovered a viral alarm switch within human cells. This critical mechanism allows the body to detect intruders and launch a counter-attack before a virus can multiply and cause widespread damage.
The Secret Weapon: Protein DZIP3
The research, led by Dr. Santosh Chauhan and published in The EMBO Journal, centers on a specific protein called DZIP3. For roughly seven years, Dr. Chauhan’s team operated on a hypothesis that certain human proteins could perform a dual role: acting as both the sensor that finds viral genetic material and the trigger that alerts the immune system.
The study confirms that DZIP3 is exactly that "dual-action" protein. The process works in a sophisticated sequence:
- Detection: When a virus enters a cell, DZIP3 identifies the presence of viral RNA.
- Activation: Upon detection, the protein undergoes a structural change, effectively "switching" itself on.
- Mobilization: Once activated, DZIP3 migrates to the mitochondria—the energy factories of the cell.
- The Alarm: At the mitochondria, it tags and activates major immune defense proteins, which then release Type-I interferons to halt viral replication.
Broad Protection Against Deadly Viruses
What makes this discovery particularly significant is the breadth of its application. The research team demonstrated that this DZIP3 pathway provides a shield against a variety of dangerous pathogens. The "alarm switch" was found to be effective against:
- SARS-CoV-2 (the virus responsible for COVID-19)
- Chikungunya
- Japanese Encephalitis
The Path to New Antiviral Drugs
The discovery isn't just theoretical; it has immediate implications for future medicine. Dr. Chauhan’s team is now working on developing small-molecule drug candidates designed to target and amplify the activity of DZIP3. By artificially boosting this natural sensor, scientists hope to enhance the body's innate antiviral immunity.
"Discovering how DZIP3 senses viral RNA and directly triggers the cell's immune machinery gives us a deeper understanding of human immunity," stated Dr. Santosh Chauhan, Senior Principal Scientist at CSIR-CCMB. "Uncovering these natural cell defence mechanisms opens up exciting new possibilities, and targeting DZIP3 with small molecules could lead to broad-spectrum antiviral therapies against emerging viral threats."
Collaboration and Support
The study was spearheaded by first author Dr. Rinku Sahu, with support from various national and international collaborators. This pivotal research was funded by the Department of Biotechnology (DBT), Government of India, marking a significant contribution to the global understanding of how humans fight off infectious diseases.